Home › Funds › TCG Crossover Management, LLC › ALXO
TCG Crossover Management, LLC position in ALXO
ALX ONCOLOGY HLDGS INC · Health Care
TCG Crossover Management, LLC reported holding 5,655,487 shares of ALXO (ALX ONCOLOGY HLDGS INC) in its Q2 2026 13F filing — a position valued at US$11.7M, representing 0.28% of its reported portfolio and ranking #45 among its reported holdings. TCG Crossover Management, LLC has disclosed ALXO holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How TCG Crossover Management, LLC's ALXO position evolved
TCG Crossover Management, LLC first disclosed a stake in ALXO in Q1 2026 at 13,011,849 shares (US$26.1M). Across 2 filings, TCG Crossover Management, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 5,655,487 shares valued at US$11.7M — a reduction of -7,356,362 shares quarter over quarter.. Notable position changes include a 57% trim in Q2 2026 (shares fell 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 13.01M | $26.09M | New |
| Q2 2026 | 5.66M | $11.71M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALXO and 13F data
ALXO (ALX ONCOLOGY HLDGS INC) is a Health Care company. 35 other funds we track also report a position in ALXO — the largest reported positions include venBio Partners LLC (US$26.7M), Redmile Group, LLC (US$15.3M), SILVERARC CAPITAL MANAGEMENT, LLC (US$11.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALXO
- venBio Partners LLC 12.88M sh · $26.67M · Q2 2026
- Redmile Group, LLC 7.39M sh · $15.30M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 5.74M sh · $11.89M · Q2 2026
- Vivo Capital, LLC 3.18M sh · $6.59M · Q2 2026
- 5AM Venture Management, LLC 3.06M sh · $6.33M · Q2 2026
- Almitas Capital LLC 2.94M sh · $6.08M · Q2 2026
More on TCG Crossover Management, LLC
FAQ
How long has TCG Crossover Management, LLC held ALXO?
TCG Crossover Management, LLC has disclosed ALXO holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is TCG Crossover Management, LLC's current position in ALXO?
As of Q2 2026, TCG Crossover Management, LLC holds 5.66M shares of ALXO (ALX ONCOLOGY HLDGS INC), valued at $11.71M, representing 0.28% of its reported portfolio and ranking #45.
Has TCG Crossover Management, LLC been buying or selling ALXO?
In the latest 13F filing (Q2 2026), TCG Crossover Management, LLC reduced its position in ALXO.
Which other funds hold ALXO?
Other major institutional holders of ALXO include venBio Partners LLC, Redmile Group, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.